AstraZeneca announced its COVID-19 vaccine candidate produced a similar immune response in both older and younger adults. The news comes just days after U.S. health regulators gave the company permission to resume trials following a brief pause.
- AstraZeneca has been working with the University of Oxford on a potential vaccine and its candidate is considered one of the most advanced.
- The company had to suspend trials in the U.S. in September after a participant developed a neurological condition. Despite only recieving permission to resume trials in the U.S. last week, the company had already continued trials in countries such as the U.K., South Africa, and Brazil.
- There are currently more than 43 million confirmed cases of COVID-19 globally and at least 1.16 million people have died. In the U.S. there are at least 8.7 million confirmed cases and more than 220,000 deaths.
- Dr. Anthony Fauci said the U.S. will know by early December if any potential vaccine candidates work, but that an effective vaccine won't be widely available until several months into 2021.